• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Aisling Capital

edit

Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.

Recent Milestones

edit

• 
  Aisling Capital invested in TRIA Beauty. (6/3/13)
  Posted 6/3/13 at 10:11pm via dowjones.com
• 
  Aisling Capital invested in ViewRay. (5/21/13)
  Posted 5/21/13 at 7:18pm via pehub.com
• 
  Aisling Capital invested in Esperion Therapeutics. (4/25/13)
  Posted 4/26/13 at 11:15pm via businesswire.com
• 
  Aisling Capital invested in Versartis. (1/15/13)
  Posted 1/15/13 at 6:53pm via fiercebiotech.com
• 
  Aisling Capital invested in Ambit Biosciences. (11/6/12)
  Posted 11/7/12 at 3:16am via yahoo.com
• 
  Aisling Capital invested in Aragon Pharmaceuticals. (10/4/12)
  Posted 10/5/12 at 2:10am via prnewswire.com
• 
  Aisling Capital invested in Agile Therapeutics. (7/19/12)
  Posted 7/19/12 at 6:07pm via finsmes.com
• 
  Aisling Capital invested in ViewRay. (3/13/12)
  Posted 3/13/12 at 6:47pm via finsmes.com
• 
  Aisling Capital invested in LensAR. (3/12/12)
  Posted 3/12/12 at 9:11pm via lensar.com
• 
  Aisling Capital invested in CeNeRx BioPharma. (2/3/12)
  Posted 2/3/12 at 3:10am via onbiovc.com
• 
  Aisling Capital invested in Roka Bioscience. (1/8/12)
  Posted 1/8/12 at 7:22pm via prnewswire.com
• 
  Aisling Capital invested in ViewRay. (9/2/11)
  Posted 9/1/11 at 10:14pm via wraltechwire.com
• 
  Aisling Capital invested in T2 Biosystems. (8/10/11)
  Posted 8/10/11 at 5:46pm via masshightech.com
• 
  Aisling Capital invested in NextWave Pharmaceuticals. (1/11/11)
  Posted 1/11/11 at 7:30pm via finsmes.com
• 
  Aisling Capital invested in TRIA Beauty. (9/10/10)
  Posted 9/12/10 at 7:09pm via finsmes.com
• 
  Aisling Capital invested in ViewRay. (8/25/10)
  Posted 8/25/10 at 9:05pm via viewray.com

Investments

Videos

Sources

1. Cosmetic Laser Device Maker Tria Beauty Raises $40.5M After Scrapped IPO (pevc.dowjones.com) [edit]
2. ViewRay Raises Fresh $15M for Its Medical Imaging Technology (pehub.com) [edit]
3. Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials (businesswire.com) [edit]
4. Versartis pockets $25M C round as it looks to PhII growth hormone study (fiercebiotech.com) [edit]
5. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia (finance.yahoo.com) [edit]
6. Aragon Pharmaceuticals Raises $50 Million in Series D Financing to Advance Promising Therapeutic Candidates for Hormone-Driven Cancers (prnewswire.com) [edit]
7. Agile Therapeutics Closes $40M Series C Financing (finsmes.com) [edit]
8. ViewRay Closes $45M Series C Venture Capital Financing (finsmes.com) [edit]
9. LensAR Raises $24 Million in Private Financing to Support Commercial Launch of LensAR Laser System (lensar.com) [edit]
10. CeNeRx BioPharma, Inc.: Series D $4.6M (onbiovc.com) [edit]
11. Roka Bioscience Secures $47.5 Million in Series D Financing (prnewswire.com) [edit]
12. MRI-guided radiotherapy firm ViewRay gets $10M in new funding (wraltechwire.com) [edit]
13. T2 Biosystems closes $23M Series D financing (masshightech.com) [edit]
14. NextWave Pharmaceuticals Raises $45m in a Series C Financing (finsmes.com) [edit]
15. TRIA Beauty Raises $15.6M (finsmes.com) [edit]
16. ViewRay Secures Series C Financing (viewray.com) [edit]
17. AltAssets (altassets.com) [edit]
18. Aragon Pharma readies first cancer trial after $22M B round (fiercebiotech.com) [edit]
19. TransEnterix, Inc.: Series B $55M (onbiovc.com) [edit]
20. Xanodyne Pharmaceuticals, Inc.: Series D $38M (onbiovc.com) [edit]
21. Cempra Pharmaceuticals, Inc.: Series C $46M (onbiovc.com) [edit]
22. Esperion Therapeutics Completes $22.75M Series A Financing (esperion.com) [edit]
23. Nutmeg State biotech lands $25.8M in round one (masshightech.com) [edit]
24. EDGAR [edit]